COVID-19 Virus Test
Target Dx Laboratory is serving communities nationwide during the pandemic
Target DX Laboratory is striving to mobilize the United States, working with our industry partners to recover and retain when it comes to testing for COVID-19. By putting every possible effort to contribute, we have achieved to diagnose the virus successfully, making a difference in the healthcare sector.
Target DX laboratory keeps working closely with state, local and federal authorities, and health care officials for the same cause. And, we have made the test available for the patients and potential affectees with the symptoms. Even though we do not hesitate to provide our services to those with cold symptoms.
COVID-19 Antibody Test
Antibody tests for COVID-19 provide information about whether you have already been infected with Sars-CoV-2 and are immune. Besides, this serological test assesses your immune system has responded to the infection, not in the situation of virus presence.
AAntibody tests are not done with a throat swab, but with a simple blood draw. It is not the virus that is measured, but its antibodies. Since it takes the immune system about ten days to make antibodies when infected, these tests cannot detect an active infection.
Donors with positive COVID-19 antibody affectees have an opportunity to help those that are currently infected with the SARS-CoV-2. Target DX Laboratory deals with this part of the testing. This test enables you to have information about the COVID-19 antibody in your blood, making you confident enough to fight against the pandemic.
Lung Cancer Test
The LCDT1 is a simple blood test that detects early stage non-small cell lung cancer with 95% accuracy.
The LCDT1 is a blood test for early detection of Non-Small Cell Lung Cancer (NSCLC). The test is indicated for patients with an indeterminate lung nodule or a long history of smoking.
The ACS predicts about 228,150 new lung cancer cases and 142,670 deaths for 2019 in the United States. Lung cancer is commonly diagnosed at a late stage and has a global estimated mortality rate of 84.2%.
Early detection of NSCLC greatly increase the survival rate of patients. Detection at Stage I or II allows for surgical intervention of the cancer tissues. If detected at Stage I and treated, the 10-year survival rate is 88-92% .
The Respiratory Panel allows you to determine if you have SARS-CoV-2 (COVID-19), Influenza Virus ( Flu A,B,C), or Pneumonia (RSV).
Cytokine storm panels include inflammatory markers looked at by researchers developing drugs or vaccines or studying diseases.
We provided affordable CRO assay services to run your panel as (RUO or CLIA) or use our cytokine storm and other panels.